Literature DB >> 1998398

Mortality from scleroderma in England and Wales 1968-1985.

A J Silman1.   

Abstract

Mortality data for scleroderma derived from death certificates from England and Wales for the years 1968-1985 were analysed. The overall crude mortalities were 0.9 and 3.8 per million per year in men and women respectively, which are similar to comparable data from the United States. There has been a small but statistically significant increase in mortality of 3% a year over this period, possibly reflecting an underlying increasing trend in incidence. Such analyses are subject to the limitation of the accuracy of death certificates, but in a disease as rare as scleroderma the death rates provide useful data on the trends in occurrence and death from this disease.

Entities:  

Mesh:

Year:  1991        PMID: 1998398      PMCID: PMC1004345          DOI: 10.1136/ard.50.2.95

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  5 in total

1.  Prevalence of scleroderma spectrum disorders in the general population of South Carolina.

Authors:  H R Maricq; M C Weinrich; J E Keil; E A Smith; F E Harper; A I Nussbaum; E C LeRoy; A R McGregor; F Diat; E J Rosal
Journal:  Arthritis Rheum       Date:  1989-08

2.  An epidemiological study of scleroderma in the West Midlands.

Authors:  A Silman; S Jannini; D Symmons; P Bacon
Journal:  Br J Rheumatol       Date:  1988-08

3.  Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate. Eleven-year follow-up of an epidemiological study.

Authors:  P Allebeck; A Ahlbom; E Allander
Journal:  Scand J Rheumatol       Date:  1981       Impact factor: 3.641

4.  The death certificate in rheumatoid arthritis.

Authors:  E C Atwater; R F Jacox
Journal:  Arthritis Rheum       Date:  1967-06

5.  Captopril in the treatment of scleroderma renal crisis.

Authors:  R H Thurm; J C Alexander
Journal:  Arch Intern Med       Date:  1984-04
  5 in total
  6 in total

Review 1.  Epidemiology of scleroderma.

Authors:  A J Silman
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

2.  How can treatment of systemic sclerosis be improved?. By setting up a national database of all cases and entering patients into trials. UK Scleroderma Study Group.

Authors: 
Journal:  BMJ       Date:  1998-08-01

3.  Systemic sclerosis is associated with knee arthroplasty outcomes: a National US study.

Authors:  Jasvinder A Singh; John D Cleveland
Journal:  Clin Rheumatol       Date:  2019-08-23       Impact factor: 2.980

4.  Mortality and causes of death in a Swedish series of systemic sclerosis patients.

Authors:  R Hesselstrand; A Scheja; A Akesson
Journal:  Ann Rheum Dis       Date:  1998-11       Impact factor: 19.103

5.  Mortality trends in systemic sclerosis in France and USA, 1980-1998: an age-period-cohort analysis.

Authors:  Solen Kernéis; Pierre-Yves Boëlle; Rebecca Freeman Grais; Gérard Pavillon; Eric Jougla; Antoine Flahault; Lone Simonsen; Thomas Hanslik
Journal:  Eur J Epidemiol       Date:  2009-11-13       Impact factor: 8.082

6.  Endothelin-1 in systemic sclerosis.

Authors:  Mehrdad Aghaei; Farhad Gharibdost; Habib Zayeni; Maryam Akhlaghi; Sima Sedighi; Abduo Rahman Rostamian; Naser Aghdami; Mahdieh Shojaa
Journal:  Indian Dermatol Online J       Date:  2012-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.